Currently browsing tag

core-earnings

Diagnostics, Tamiflu help Roche full-year sales beat poll

ZURICH (Reuters) – Swiss drugmaker Roche expects sales and profits to grow at a similar pace to last year, after a strong performance by its diagnostics unit and flu drug Tamiflu helped full-year sales beat expectations. Stripping out the impact of currency fluctuations, the world's largest maker of cancer drugs forecast 2015 sales to grow in the low-to-mid single digit range, while core earnings per share (EPS) should grow more than sales. Full-year sales rose 1 percent to 47.5 billion Swiss francs ($52.5 billion), generating flat core earnings per share (EPS) of 14.29 Swiss francs. …